Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

1,766 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab.
Karp JE, Gojo I, Pili R, Gocke CD, Greer J, Guo C, Qian D, Morris L, Tidwell M, Chen H, Zwiebel J. Karp JE, et al. Among authors: qian d. Clin Cancer Res. 2004 Jun 1;10(11):3577-85. doi: 10.1158/1078-0432.CCR-03-0627. Clin Cancer Res. 2004. PMID: 15173063 Clinical Trial.
Platelets take up the monoclonal antibody bevacizumab.
Verheul HM, Lolkema MP, Qian DZ, Hilkes YH, Liapi E, Akkerman JW, Pili R, Voest EE. Verheul HM, et al. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5341-7. doi: 10.1158/1078-0432.CCR-07-0847. Epub 2007 Sep 12. Clin Cancer Res. 2007. PMID: 17855648
1,766 results